Chronic Myeloid Leukemia

Chronic Myeloid Leukemia Article

Chronic myelogenous leukemia Classifications and external resources The Philadelphia chromosome as seen by metaphase FISH. ICD-10 C92.1 ICD-9 205.1 ICD-O: M9863/3 DiseasesDB 2659 MedlinePlus 000570 eMedicine med/371

Chronic Myeloid Leukemia News

Chronic Myeloid Leukemia: Diagnosis and Treatment

Chronic myeloid leukemia (CML) has become a model in research and management among malignant disorders. Since the discovery of the presence of a unique and constant chromosomal abnormality slightly more than 40 years ago, substantial progress has been made in the understanding of the biology of the

Chronic Myeloid Leukemia: Current Application of Cytogenetics and Molecular Testing for Diagnosis and Treatment

Chronic myeloid leukemia provides an illustrative disease model for both molecular pathogenesis of cancer and rational drug therapy. Chronic myeloid leukemia is a clonal stem cell disease caused by an acquired somatic mutation that fuses, through chromosomal translocation, the abl and bcr genes on

Imatinib-induced nail hyperpigmentation in chronic myeloid leukemia

Sir, Imatinib mesylate has revolutionized the treatment of chronic myeloid leukemia (CML) and has been recently approved as first-line treatment. Most of the patients receiving imatinib experience hematological or non-hematological side effects. Skin changes are the most common non-hematological

Oral agent shows promise for chronic myeloid leukemia.

SAN DIEGO - A new oral drug for patients with Gleevec-resistant chronic myeloid leukemia led to remission in 86% of patients in a phase I trial. Obviously we're excited by that, Charles L. Sawyers, M.D., said at a press briefing during the annual meeting of the American Society of Hematology. The

The chronic leukemias of myeloid origin.

Chronic leukemias of myeloid origin (CLMO) disorders are the second major category of chronic leukemias. The first major category of chronic leukemias, leukemias of lymphoid origin, was discussed in part one of this two-part series (see MLO, November 1998, p. 26). This group of neoplastic disorders